COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

Moores UCSD Cancer Center Receives $6 Million NIH Contract to Identify Vaccine-Enhancing Substances

 

October 12, 2009  |  

Researchers at the Moores UCSD Cancer Center have received $6 million from the National Institutes of Health to spend the next five years looking for, testing and developing chemicals called “adjuvants” that they hope will make current vaccines more effective.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded approximately $60 million over five years to six institutions in the United States, with the goal of identifying and characterizing novel adjuvants – substances that can be added to vaccines to enhance the protective immune response they induce. These compounds will be tested in animal models and human cells to determine how well they stimulate immune responses.  

 

Dennis Carson

Dennis Carson, MD

 

According to Moores Cancer Center director Dennis Carson, MD, who leads the Cancer Center team, it’s only recently that scientists have begun to understand how adjuvants work through specific protein receptors.

“Our aim is to find chemicals that can activate newly discovered receptors in order to stimulate immunity and act as adjuvants,” said Carson. The work will involve using sophisticated “high-throughput” chemical screening techniques, resulting in the selection of drug candidates for continued testing. “It’s a drug discovery project.”

“We’d like to be able to manipulate and train the immune system and at the same time find and better understand its receptors and targets,” Carson added. “Our job is drug development that will intersect with the basic biology and clinical testing done by others.”

One goal for the overall study is to make stronger, more specific adjuvants for current vaccines. Carson envisions the day when a flu vaccine, for example, could require only one one-hundredth of the current dose, meaning vaccine stocks could last longer. At the same time, better adjuvants could enhance the immune reactions of immune-challenged individuals such as the elderly.

In addition to biologists and chemists at the Cancer Center, the Moores Cancer Center team is collaborating with colleagues at the University of California, San Francisco and Life Technologies, a San Diego-based company.

Other institutions receiving contracts for 2009 include the University of Michigan, Ann Arbor, the University of Kansas, Lawrence, the University of Washington School of Medicine, Seattle, Corixa Corporation (now part of GlaxoSmithKline Biologicals), Hamilton, Mont., and Mount Sinai School of Medicine, New York City.

The Moores UCSD Cancer Center is one of the nation’s 40 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer.

# # #

Media Contact: Steve Benowitz, 619-543-6163, sbenowitz@ucsd.edu


Related Specialties

Cancer

Infectious Diseases



Media Contact

Share This Article


Related News

5/6/2022
UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formati ...
4/29/2022
Trauma physicians at UC San Diego Health attribute the rise in injuries to a height increase of the border wall at U.S.-Mexico border.
4/28/2022
Researchers at UC San Diego School of Medicine report that high-frequency spinal cord stimulation proved more effective at improving perceived pain reduction than low-frequency SCS in patients studied ...
4/25/2022
Epilepsy treatment, and hopefully quality of life for one 18-year-old patient, receives robotic boost at UC San Diego Health.



Follow Us